Hailey Krzyston1, Brian Morse2, Danielle Deperalta3, Anupam Rishi4, Roger Kayaleh1, Ghassan El-Haddad2, Johnna Smith2, Mihaela Druta3, Bela Kis2. 1. Department of Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center, Tampa, Florida, USA;University of South Florida, Morsani College of Medicine, Tampa, Florida, USA. 2. Department of Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center, Tampa, Florida, USA. 3. Department of Sarcoma Oncology, Moffitt Cancer Center, Tampa, Florida, USA. 4. Department of Radiation Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
Abstract
PURPOSE: The purpose of this study was to determine the safety and efficacy of liver-directed therapies in patients with unresectable metastatic leiomyosarcoma to the liver. Liver-directed therapies included in this study were transarterial chemoembolization with doxorubicin eluting beads (DEB-TACE), yttrium-90 (Y90) radioembolization, and percutaneous microwave ablation. METHODS: This is a single institution retrospective study of unresectable metastatic leiomyosarcoma to the liver treated with DEB-TACE, radioembolization, or microwave ablation. DEB-TACE was performed using 70-150 or 100-300 µ doxorubicin-loaded drug-eluting LC beads. Radioembolization was performed using Y90 glass microspheres. Electronic medical records were retrospectively reviewed to evaluate clinical and biochemical toxicities, tumor response on imaging, overall survival (OS), and liver progression-free survival (PFS). RESULTS: A total of 24 patients with metastatic leiomyosarcoma to the liver who underwent liver-directed treatment were identified (8 males, 16 females; average age, 62.8±11.4 years). Of these patients, 13 underwent DEB-TACE, 6 underwent Y90, and 5 underwent ablation. Three patients received a combination of treatments: one received Y90 followed by DEB-TACE, one received ablation followed by DEB-TACE, and one received ablation followed by Y90. Of the 24 patients, 19 received prior chemotherapy. At 3-month follow-up, grade 1 or 2 lab toxicities were found in 20 patients; 3 patients had grade 3 toxicities. A grade 3 clinical toxicity was reported in one patient. MELD score was 7.5±1.89 at baseline and 8.8±4.2 at 3 months. Median OS was 59 months (95% CI, 39.8-78.2) from diagnosis, 27 months (95% CI, 22.9-31.0) from development of liver metastasis, and 9 months (95% CI, 0-21.4) from first liver-directed treatment. Median liver PFS was 9 months (95% CI, 1.4-16.6). CONCLUSION: Treatment with liver-directed therapies for patients with unresectable metastatic leiomyosarcoma to the liver is safe and can improve overall survival, with OS after liver-directed therapy being similar to patients who underwent surgical resection.
PURPOSE: The purpose of this study was to determine the safety and efficacy of liver-directed therapies in patients with unresectable metastatic leiomyosarcoma to the liver. Liver-directed therapies included in this study were transarterial chemoembolization with doxorubicin eluting beads (DEB-TACE), yttrium-90 (Y90) radioembolization, and percutaneous microwave ablation. METHODS: This is a single institution retrospective study of unresectable metastatic leiomyosarcoma to the liver treated with DEB-TACE, radioembolization, or microwave ablation. DEB-TACE was performed using 70-150 or 100-300 µ doxorubicin-loaded drug-eluting LC beads. Radioembolization was performed using Y90 glass microspheres. Electronic medical records were retrospectively reviewed to evaluate clinical and biochemical toxicities, tumor response on imaging, overall survival (OS), and liver progression-free survival (PFS). RESULTS: A total of 24 patients with metastatic leiomyosarcoma to the liver who underwent liver-directed treatment were identified (8 males, 16 females; average age, 62.8±11.4 years). Of these patients, 13 underwent DEB-TACE, 6 underwent Y90, and 5 underwent ablation. Three patients received a combination of treatments: one received Y90 followed by DEB-TACE, one received ablation followed by DEB-TACE, and one received ablation followed by Y90. Of the 24 patients, 19 received prior chemotherapy. At 3-month follow-up, grade 1 or 2 lab toxicities were found in 20 patients; 3 patients had grade 3 toxicities. A grade 3 clinical toxicity was reported in one patient. MELD score was 7.5±1.89 at baseline and 8.8±4.2 at 3 months. Median OS was 59 months (95% CI, 39.8-78.2) from diagnosis, 27 months (95% CI, 22.9-31.0) from development of liver metastasis, and 9 months (95% CI, 0-21.4) from first liver-directed treatment. Median liver PFS was 9 months (95% CI, 1.4-16.6). CONCLUSION: Treatment with liver-directed therapies for patients with unresectable metastatic leiomyosarcoma to the liver is safe and can improve overall survival, with OS after liver-directed therapy being similar to patients who underwent surgical resection.
Authors: Mizuki Nishino; Jyothi P Jagannathan; Nikhil H Ramaiya; Annick D Van den Abbeele Journal: AJR Am J Roentgenol Date: 2010-08 Impact factor: 3.959
Authors: Mary A Maluccio; Anne M Covey; Johanna Schubert; Lynn A Brody; Constantinos T Sofocleous; George I Getrajdman; Ronald DeMatteo; Karen T Brown Journal: Cancer Date: 2006-10-01 Impact factor: 6.860
Authors: Marcus C B Tan; Murray F Brennan; Deborah Kuk; Narasimhan P Agaram; Cristina R Antonescu; Li-Xuan Qin; Nicole Moraco; Aimee M Crago; Samuel Singer Journal: Ann Surg Date: 2016-03 Impact factor: 12.969
Authors: Kent T Sato; Robert J Lewandowski; Mary F Mulcahy; Bassel Atassi; Robert K Ryu; Vanessa L Gates; Albert A Nemcek; Omar Barakat; Al Benson; Robert Mandal; Mark Talamonti; Ching-Yee O Wong; Frank H Miller; Steven B Newman; John M Shaw; Kenneth G Thurston; Reed A Omary; Riad Salem Journal: Radiology Date: 2008-03-18 Impact factor: 11.105
Authors: Claire Goumard; Leonardo P Marcal; Wei-Lien Wang; Neeta Somaiah; Masayuki Okuno; Christina L Roland; Ching-Wei D Tzeng; Yun Shin Chun; Barry W Feig; Jean-Nicolas Vauthey; Claudius Conrad Journal: Ann Surg Oncol Date: 2017-11-07 Impact factor: 5.344
Authors: Rebecca A Gladdy; Li-Xuan Qin; Nicole Moraco; Narasimhan P Agaram; Murray F Brennan; Samuel Singer Journal: Ann Surg Oncol Date: 2013-01-25 Impact factor: 5.344
Authors: R Cianni; G Pelle; E Notarianni; A Saltarelli; P Rabuffi; O Bagni; L Filippi; E Cortesi Journal: Eur Radiol Date: 2012-07-27 Impact factor: 5.315
Authors: R L Jones; J McCall; A Adam; D O'Donnell; S Ashley; O Al-Muderis; K Thway; C Fisher; I R Judson Journal: Eur J Surg Oncol Date: 2010-01-08 Impact factor: 4.424
Authors: Stefano Testa; Nam Q Bui; David S Wang; John D Louie; Daniel Y Sze; Kristen N Ganjoo Journal: Cancers (Basel) Date: 2022-01-10 Impact factor: 6.639